50825-96-2

Upstream product

• 31206-25-4 3,5-dinitrobenzene-1-sulfonyl chloride 
• 28084-45-9 3,5-dinitro-benzenesulfonic acid 
• 84615-18-9 C₆H₄N₄O₈S 
• 618-87-1 3, 5-dinitroaniline 

Downstream Products

• 84615-18-9 C₆H₄N₄O₈S 
• 1044271-92-2 3-amino-5-nitro-benzenesulfonamide 
• 1445880-82-9 3-(4-fluorophenoxy)-5-nitrobenzenesulfonamide 
• 1445879-74-2 N-cyclopropyl-4-((3-(4-fluorophenoxy)-5-sulfamoylphenyl)amino)-7-(4-methoxypyrimidin 5-yl)quinoline-3-sulfonamide 
• 1445880-81-8 7-bromo-N-cyclopropyl-4-(3-(4-fluorophenoxy)-5-sulfamoylphenylamino)quinoline-3-sulfonamide 
• 1445879-75-3 N-cyclopropyl-4-((3-(4-fluorophenoxy)-5-sulfamoylphenyl)amino)-7-(pyrimidin-5-yl)quinoline-3-sulfonamide 
• 1445880-83-0 3-amino-5-(4-fluorophenoxy)benzenesulfonamide 
• 1445879-76-4 N-cyclopropyl-7-(3,5-dimethyl-1H-pyrazol-4-yl)-4-((3-(4-fluorophenoxy)-5-sulfamoylphenyl)amino)quinoline-3-sulfonamide 
• 1445879-77-5 N-cyclopropyl-4-((3-(4-fluorophenoxy)-5-sulfamoylphenyl)amino)-7-(1,3,5-trimethyl-1H-pyrazol-4-yl)quinoline-3-sulfonamide 
• 1445879-78-6 N-cyclopropyl-4-((3-(4-fluorophenoxy)-5-sulfamoylphenyl)amino)-7-(pyridin-3-yl)quinoline-3-sulfonamide 
• 1445879-79-7 N-cyclopropyl-4-((3-(4-fluorophenoxy)-5-sulfamoylphenyl)amino)-7-(pyridin-2-yl)quinoline-3-sulfonamide 
• 1445880-88-5 3-(N-cyclopropylsulfamoyl)-4-(3-(4-fluorophenoxy)-5 sulfamoylphenylamino)quinolin-7-ylboronic acid 
• 1445879-80-0 N-cyclopropyl-4-((3-(4-fluorophenoxy)-5-sulfamoylphenyl)amino)-7-(2-methoxyphenyl)quinoline-3-sulfonamide 
• 65809-59-8 3,5-diaminobenzenesulfonamide 

Relevant academic research and scientific papers

AROMATIC SULFONAMIDE DERIVATIVES AND THEIR USE AS ANATAGON I STS OR NEGATIVE ALLOSTERIC MODULATORS OF P2X4

Substituted aromatic sulfonamides of formula (I), pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease.

CHEMICAL COMPOUNDS

The invention is directed to substituted quinoline derivatives. Specifically, the invention is directed to compounds according to Formula I: wherein R, R1, R2, R3 and R4 are defined herein. The compounds of the invention are inhibitors of lactate dehydrogenase A and can be useful in the treatment of cancer and diseases associated with tumor cell metabolism, such as cancer, and more specifically cancers of the breast, colon, prostate and lung. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting lactate dehydrogenase A activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

PYRIMIDINE DERIVATIVES

The invention concerns benzamide compounds of Formula (I), or a pharmaceutically acceptable salt thereof, where R1, ring A, n, R3, and R4 are as defined in the description. The present invention also relates to processes for the preparation of such compounds, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an antiproliferative agent in the prevention or treatment of tumours or other proliferative conditions which are sensitive to the inhibition of EphB4, and/or EphA2 and/or Src kinases.

Pteridinone derivatives as PI3-kinases inhibitors

New compounds of formula 1 are provided which by virtue of their pharmaceutical activity as PI3-kinase modulators may be used in the therapeutic field for the treatment of inflammatory or allergic diseases. Examples of these include inflammatory and allergic respiratory complaints, inflammatory diseases of the gastro-intestinal tract and motor apparatus, inflammatory and allergic skin diseases, inflammatory eye diseases, diseases of the nasal mucosa, inflammatory or allergic conditions involving autoimmune reactions or inflammations of the kidney.

Inhibitors of the tyrosine kinase EphB4. Part 2: Structure-based discovery and optimisation of 3,5-bis substituted anilinopyrimidines

Crystallographic studies of a range of 3-substituted anilinopyrimidine inhibitors of EphB4 have highlighted two alternative C-2 aniline conformations and this discovery has been exploited in the design of a highly potent series of 3,5-disubstituted anilin

EFFECT OF STRUCTURE ON THE KINETICS AND MECHANISM OF THE ACID-CATALYZED DECOMPOSITION OF N-NITROBENZENESULFONAMIDES

The decomposition rate of a series of ring-substituted N-nitrobenzenesulfonamides in aqueous sulfuric acid was measure by a spectrophotometric method.Decomposition of the compounds takes place both by the cleavage of the N-S bond to form the corresponding sulfonic acid, nitrous oxide, and water and by denitration.In crease in the electronegativity of the substituent in the aromatic ring promotes the denitration reaction.